1. The impairment of the Growth Hormone/Insulin-like growth factor 1 (IGF-1) axis in heart failure: A possible target for future therapy.
- Author
-
Piccioli L, Arcopinto M, Salzano A, D'Assante R, Schiavo A, Stagnaro FM, Lombardi A, Panicara V, Valente P, Vitale G, Sarullo FM, Giallauria F, and Marra AM
- Subjects
- Chronic Disease, Heart Failure drug therapy, Human Growth Hormone therapeutic use, Humans, Heart Failure metabolism, Human Growth Hormone metabolism, Insulin-Like Growth Factor I metabolism
- Abstract
Hormonal abnormalities are quite common in chronic heart failure (CHF). The most studied hormonal axis in CHF is the impairment of Growth Hormone (GH)/Insulin Growth Factor-1(IGF-1), which in turn is defined either by a blunted response to GH stimulation test or low serum IGF-1 values. Several independent groups reported that the presence of an abnormal GH/IGF-1 status in CHF is associated with a more severe disease, impaired functional capacity and reduced Survival rates. After the first encouraging results, double -blind controlled trials showed a neutral effect of the GH administration in patients. However, further studies reported positive results, when a GH-therapy is implemented only in those patients presenting a GH deficiency (replacement therapy).
- Published
- 2018
- Full Text
- View/download PDF